UY26265A1 - CALCIOLYTIC COMPOUNDS - Google Patents

CALCIOLYTIC COMPOUNDS

Info

Publication number
UY26265A1
UY26265A1 UY26265A UY26265A UY26265A1 UY 26265 A1 UY26265 A1 UY 26265A1 UY 26265 A UY26265 A UY 26265A UY 26265 A UY26265 A UY 26265A UY 26265 A1 UY26265 A1 UY 26265A1
Authority
UY
Uruguay
Prior art keywords
calciolytic
compounds
disorders
new methods
bone diseases
Prior art date
Application number
UY26265A
Other languages
Spanish (es)
Inventor
Maxine Gowen Larry Suva Stroup
Original Assignee
Smithkline Beecham Corp Y Nps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp Y Nps filed Critical Smithkline Beecham Corp Y Nps
Publication of UY26265A1 publication Critical patent/UY26265A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan nuevos métodos para tratar enfermedades o trastornos de los huesos.New methods are provided to treat bone diseases or disorders.

UY26265A 1999-07-31 2000-07-31 CALCIOLYTIC COMPOUNDS UY26265A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
UY26265A1 true UY26265A1 (en) 2001-03-16

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26265A UY26265A1 (en) 1999-07-31 2000-07-31 CALCIOLYTIC COMPOUNDS

Country Status (21)

Country Link
EP (1) EP1200076A4 (en)
JP (1) JP2003505502A (en)
KR (1) KR20020016928A (en)
CN (1) CN1367687A (en)
AU (1) AU764716B2 (en)
BR (1) BR0012921A (en)
CA (1) CA2380081A1 (en)
CO (1) CO5180628A1 (en)
CZ (1) CZ2002360A3 (en)
EC (1) ECSP003590A (en)
HK (1) HK1046238A1 (en)
HU (1) HUP0202167A3 (en)
IL (1) IL147875A0 (en)
MX (1) MXPA02001204A (en)
NO (1) NO20020466L (en)
PE (1) PE20010459A1 (en)
PL (1) PL353318A1 (en)
TR (1) TR200200278T2 (en)
UY (1) UY26265A1 (en)
WO (1) WO2001008673A1 (en)
ZA (1) ZA200200784B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
UY28089A1 (en) 2002-11-26 2004-06-30 Smithkline Beecham Corp CALCILITICAL COMPOUNDS
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (en) * 2017-02-15 2018-08-21 四川大学 A kind of NPS-2143 is used for the new application of antibacterial
CN116173187B (en) * 2023-03-14 2024-05-10 哈尔滨医科大学 Application of calcitonin in preparation of medicine for preventing and treating restenosis in stent, medicine coating stent and preparation method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG99290A1 (en) * 1996-04-09 2003-10-27 Nps Pharma Inc Calcilytic compounds
AR018177A1 (en) * 1998-04-08 2001-10-31 Smithkline Beecham Corp CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
AR014975A1 (en) * 1998-04-08 2001-04-11 Nps Pharma Inc CALCILITICAL COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Also Published As

Publication number Publication date
CO5180628A1 (en) 2002-07-30
BR0012921A (en) 2002-06-18
HUP0202167A3 (en) 2006-07-28
CN1367687A (en) 2002-09-04
WO2001008673A1 (en) 2001-02-08
CA2380081A1 (en) 2001-02-08
JP2003505502A (en) 2003-02-12
ZA200200784B (en) 2003-01-29
EP1200076A4 (en) 2005-02-09
TR200200278T2 (en) 2002-06-21
PL353318A1 (en) 2003-11-17
CZ2002360A3 (en) 2002-10-16
KR20020016928A (en) 2002-03-06
EP1200076A1 (en) 2002-05-02
NO20020466L (en) 2002-03-20
IL147875A0 (en) 2002-08-14
ECSP003590A (en) 2002-02-25
MXPA02001204A (en) 2004-05-21
NO20020466D0 (en) 2002-01-29
AU764716B2 (en) 2003-08-28
PE20010459A1 (en) 2001-06-11
AU6504100A (en) 2001-02-19
HK1046238A1 (en) 2003-01-03
HUP0202167A2 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
DK2052714T3 (en) Topical gel feeding system for the treatment of skin disorders
BR9911781B1 (en) illuminator for photodynamic therapy.
DE60124302D1 (en) THIAZONE DERIVATIVES FOR THE TREATMENT OF PPAR-LIFE DISEASES
ATE275145T1 (en) CHINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMORS
PE20020521A1 (en) SUBSTITUTE HETEROCYCLIC COMPOUNDS TO TREAT MULTIPLE DRUG RESISTANCE
PT967214E (en) INTRANASAL FORMULATIONS FOR THE TREATMENT OF SEXUAL DISORDERS
ID30276A (en) METHODS FOR TREATING SEXUAL DISORDERS
UY26929A1 (en) ANTIANGIOGEN POLIPEPTIDES AND METHODS TO INHIBIT THE ANGIOGENESIS
DE60021381D1 (en) CHINONIC COMPOUNDS FOR THE TREATMENT OF DISEASES
PT1325011E (en) METHODS AND COMPOUNDS FOR TREATMENT OF PROLIFERATIVE DISEASES
DE502004010131D1 (en) PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISORDERS
EE200300366A (en) Methods for treating or preventing skin diseases by CD2 binding agents
UY26265A1 (en) CALCIOLYTIC COMPOUNDS
DE69823493D1 (en) TETRAHYDROPYRIDOVERBINDUNGEN
NO20014241D0 (en) C16-unsaturated FP-selective prostaglandin analogs
PT983275E (en) NEW DERIVATIVES OF TRIPTOLIDO ADVANTAGES FOR THE TREATMENT OF AUTOMATIC DISEASES
SE9801494D0 (en) Novel use
IS5951A (en) 5HT1 antidepressant for the treatment of depression
PT1170591E (en) METHODS FOR IDENTIFYING COMBINATIONS OF IDENTITIES AS THERAPEUTIC AGENTS
YU60101A (en) Resorcinol derivatives
TR200002203T2 (en) Treatment of follicular lymphomas using inhibitors of the lysophoxin (LT) expression pathway.
DE60138371D1 (en) PROSTAGLANDINE for the treatment of light radiation produced eye diseases such as photoretinitis
PT1268482E (en) PIRANOINDOIS FOR THE TREATMENT OF GLAUCOMA
DOP2001000140A (en) ARIL AND HETEROARILSULFONATOS
IT1320192B1 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101025